Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
Status: | Active, not recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/9/2019 |
Start Date: | March 2014 |
End Date: | March 2019 |
A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of
femoropopliteal artery (SFA) in-stent restenosis (ISR).
femoropopliteal artery (SFA) in-stent restenosis (ISR).
Key Inclusion Criteria:
1. Male or non-pregnant female ≥18 years of age
2. Rutherford Clinical Category 2-4
3. Significant (≥ 50%) restenosis of a previous bare (not covered and not drug-eluting)
nitinol stent(s) in the femoropopliteal artery
4. Lesion measures between 4 and 18 cm
5. Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available
device size matrix
6. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by
angiography
7. Successful crossing and predilatation of the target lesion with a guidewire
8. At least one patent native outflow artery to the ankle, free from significant (≥50%)
stenosis as confirmed by angiography that has not previously been (nor planned to be)
revascularized
9. No other prior vascular or surgical interventions within 2 weeks before and/or planned
30 days after the protocol treatment
Key Exclusion Criteria:
1. Life expectancy of <1 year
2. Patient is currently participating in an investigational drug or other device study or
previously enrolled in this study NOTE: Enrollment in another drug or device clinical
trial during the follow up period is not allowed
3. History of stroke within 3 months
4. History of MI, thrombolysis or angina within 2 weeks of enrollment
5. Prior vascular surgery of the index limb, with the exception of remote common femoral
patch angioplasty separated by at least 2 cm from the target lesion
6. Target lesion involves a previously placed covered stent or drug-eluting stent
7. Grade 4 or 5 stent fracture (mal-aligned components or trans-axial spiral
configuration) in the restenotic stent
8. Inability to take required study medications or allergy to contrast that cannot be
adequately managed with pre- and post-procedure medication
9. Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three
tibial vessels), or planned future treatment of vascular disease distal to the target
lesion
10. Intended use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty,
scoring/cutting balloon, stents, etc.)
We found this trial at
20
sites
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: Mark Levy, MD
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Michael Silva, MD
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Flemington, New Jersey 08822
Principal Investigator: Andrey Espinoza, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Kingsport, Tennessee 37660
Principal Investigator: D. Christopher Metzger, MD
Click here to add this to my saved trials
Lakeland, Florida 33805
Principal Investigator: Fakhir Elmasri, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: S. Elissa Altin, MD
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
North Kansas City, Missouri 64116
Principal Investigator: Scott Kujath, MD
Click here to add this to my saved trials
Plymouth, Minnesota 55441
Principal Investigator: Troy Long, MD
Click here to add this to my saved trials
Providence, Rhode Island 02906
Principal Investigator: Peter Soukas, MD
Click here to add this to my saved trials
Click here to add this to my saved trials
Royal Oak, Michigan 48073
Principal Investigator: Amr Abbas, MD
Click here to add this to my saved trials
Washington, District of Columbia 20010
Principal Investigator: Nelson Bernardo, MD
Click here to add this to my saved trials
Wyoming, Michigan 49519
Principal Investigator: Jihad Mustapha, MD
Click here to add this to my saved trials